title: Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?
abstract: OBJECTIVE
  Published studies of triptans in acute migraine have shown relatively disappointing 2-hour pain-free rates, ranging from 18% to 58%, with 2- to 24-hour sustained pain-free rates from 17% to 25%. A major flaw in the design of previous studies may have contributed to disappointing results: many subjects are not truly episodic in the nature of their headaches-they discount days with mild headache and ignore days with migraine-related neck pain. Believing that neck pain is integrally related to migraine, we sought to ascertain whether early treatment with sumatriptan 85/naproxen sodium 500 (sumatriptan/naproxen) in truly episodic migraineurs is more robust than results when neck pain has not been considered.
  
  
  METHODS
  Successfully screened adult migraineurs who returned baseline diaries showing 2 to 7 migraine attacks monthly and < 15 headache and/or neck pain days/month received blister packs containing 3 sumatriptan/naproxen/1 placebo for treatment of 4 migraines. Instructions were to treat within the first 30 minutes of mild headache or neck discomfort-but only if the preceding day was completely free of both headache and neck pain.
  
  
  RESULTS
  In our study, 63.9% of patient attacks treated with sumatriptan/naproxen achieved 2-hour pain freedom compared with 33.3% of those with placebo (P < 0.001). Sustained pain freedom (2-24 hours) was achieved in 69.1% of sumatriptan/naproxen-treated attacks, compared with 23.3% with placebo (P < 0.01). More subjects using sumatriptan/naproxen achieved sustained pain freedom (than 2-hour pain freedom), due to 6 time points when the subject was sleeping/napping 2-hours post dose (5 sumatriptan/naproxen, 1 placebo), yet attested to no discomfort between 2 and 24 hours post dose. Had the attacks been scored as pain-free at 2 hours, the 2-hour pain-free and sustained pain-free rates with sumatriptan/naproxen would have been identical at 69.1% (vs 36.7% with placebo). With truly episodic migraineurs, pain freedom was significant as soon as 15 minutes following treatment with sumatriptan/naproxen (5.2% vs 0% with placebo; P < 0.01).
  
  
  CONCLUSIONS
  Our study results support a fundamental re-evaluation of the role of neck pain in migraine.
authors.affiliation: Partner, Co-Founder, Carolina Headache Institute; Professor, Department of Anesthesiology; Professor, Department of Psychiatry, University of North Carolina, Chapel Hill, NC. calhouna@carolinaheadacheinstitute.com.
authors.forename: Anne H
authors.initials: AH
authors.lastname: Calhoun
authors.forename: Sutapa
authors.initials: S
authors.lastname: Ford
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016014:Linear Models; D008297:Male; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy*; D009288:Naproxen / Q000627:therapeutic use*; D019547:Neck Pain / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement; D012008:Recurrence; D018170:Sumatriptan / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D009288:Naproxen; D018170:Sumatriptan